Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle

Melvin R Hayden, Suresh C Tyagi, Melvin R Hayden, Suresh C Tyagi

Abstract

BACKGROUND: The topical role of uric acid and its relation to cardiovascular disease, renal disease, and hypertension is rapidly evolving. Its important role both historically and currently in the clinical clustering phenomenon of the metabolic syndrome (MS), type 2 diabetes mellitus (T2DM), atheroscleropathy, and non-diabetic atherosclerosis is of great importance. RESULTS: Uric acid is a marker of risk and it remains controversial as to its importance as a risk factor (causative role). In this review we will attempt to justify its important role as one of the many risk factors in the development of accelerated atherosclerosis and discuss its importance of being one of the multiple injurious stimuli to the endothelium, the arterial vessel wall, and capillaries. The role of uric acid, oxidative - redox stress, reactive oxygen species, and decreased endothelial nitric oxide and endothelial dysfunction cannot be over emphasized.In the atherosclerotic prooxidative environmental milieu the original antioxidant properties of uric acid paradoxically becomes prooxidant, thus contributing to the oxidation of lipoproteins within atherosclerotic plaques, regardless of their origins in the MS, T2DM, accelerated atherosclerosis (atheroscleropathy), or non-diabetic vulnerable atherosclerotic plaques. In this milieu there exists an antioxidant - prooxidant urate redox shuttle. CONCLUSION: Elevations of uric acid > 4 mg/dl should be considered a "red flag" in those patients at risk for cardiovascular disease and should alert the clinician to strive to utilize a global risk reduction program in a team effort to reduce the complications of the atherogenic process resulting in the morbid - mortal outcomes of cardiovascular disease.

Figures

Figure 1
Figure 1
Metabolic syndrome: hyperuricemia. This image focuses on the "H" phenomenon consisting of the four major players in the MS: Hyperinsulinemia, Hypertension, Hyperlipidemia and the Lipotoxicity – Obesity toxicity triad, and Hyperglycemia. These players have frequently been referred to as the "deadly quartet" and the "H" phenomenon. It is important to note the central position of insulin resistance in this image and also hyperuricemia. Hyperuricemia is flanked by hyperhomocysteinemia to indicate its importance in the MS. Each of these players has its own important role and this image helps to portray the clustering effect and synergism to contribute to an overall increased oxidative – redox stress to the endothelium of the vasculature.
Figure 2
Figure 2
Multiple injurious stimuli to the endothelium in non-diabetic atherosclerosis and atheroscleropathy. This image portrays the anatomical relationship between the endothelium, intima, media and the adventitia. Each of these layers plays an important role in the development of accelerated atherosclerosis (atheroscleropathy) of the MS, PD, and overt T2DM. Of all the different layers the endothelium seems to play a critical and central role. It is placed at a critical location and acts as an interface with nutrients and toxic products not only at its luminal surface of musculo-elastic arteries but also at the endothelial extracellular matrix interface of the interstitium in capillary beds. The intima, sandwiched between the medial muscular layer and the endothelium, is the site of atherosclerosis, intimopathy, and the atheroscleropathy associated with MS, PD, and overt T2DM. There are multiple injurious stimuli to the endothelium including ROS and hyperuricemia. It is important to note that redox stress occurs upstream from inflammation by activating the nuclear transcription factor: NFkappa B [39]. Over time, individually and synergistically these injurious stimuli (table 1) result in the morbid – mortal vascular complications of MS, T2DM, atheroscleropathy, and non-diabetic atherosclerosis.
Figure 3
Figure 3
Antioxidant – prooxidant urate redox shuttle. The antioxidant – prooxidant urate redox shuttle is an important concept to understand regarding accelerated atherosclerosis. This shuttle is important in understanding the role of how the antioxidant uric acid becomes prooxidant in this environmental milieu, which results in its damaging role to the endothelium and arterial vessel wall remodeling with an elevated tension of oxidative – redox stress (ROS), accelerated atherosclerosis and arterial vessel wall remodeling.
Figure 4
Figure 4
Uncoupling of the eNOS reaction. It is important to understand the role of endothelial dysfunction in accelerated atherosclerosis and even more important to understand the role of eNOS enzyme uncoupling and how it relates to MS, PD, T2DM, and non-diabetic atherosclerosis. Oxygen reacts with the eNOS enzyme in which the tetrahydrobiopertin (BH4) cofactor has coupled nicotinamide dinucleotide phosphate reduced (NAD(P)H) emzyme with L-arginine to be converted to nitric oxide (NO) and L-citrulline. When uncoupling occurs the NAD(P)H enzyme reacts with O2 and the endothelial cell becomes a net producer of superoxide (O2•) instead of the protective endothelial NO. This figure demonstrates the additional redox stress placed upon the arterial vessel wall and capillaries in patients with MS, PD, and overt T2DM.

References

    1. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7–13.
    1. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000;283:2404–2410. doi: 10.1001/jama.283.18.2404.
    1. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164:1546–1551. doi: 10.1001/archinte.164.14.1546.
    1. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1995;141:637–644.
    1. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol. 2002;2:126–130. doi: 10.1016/S1471-4892(02)00143-1.
    1. Verdecchia P, Schillaci G, Reboldi GP, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. Hypertension. 2000;36:1072–1078.
    1. Liese AD, Hense HW, Löwel H, Döring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. Epidemiology. 1999;10:391–397. doi: 10.1097/00001648-199907000-00006.
    1. Brand FN, McGee DL, Kannel WB, Stokes J, III, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: the Framingham study. Am J Epidemiol. 1985;121:11–18.
    1. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart. 1997;78:147–153. (Part of the cluster not independent)
    1. Franse LV, Pahor M, Di Bari M, Shorr RI, Wan JY, Somes GW, Applegate WB. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP) J Hypertens. 2000;18:1149–1154. doi: 10.1097/00004872-200018080-00021.
    1. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183–1190. doi: 10.1161/01.HYP.0000069700.62727.C5.
    1. Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin. 2004;20:369–379.
    1. Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu L. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension. 2001;37:1069–1074.
    1. Gertler MM, Driskell MM, Bland EF, Garn SM, Learman J, Levine SA, Sprague HB, White PD. Clinical aspects of coronary heart disease; an analysis of 100 cases in patients 23 to 40 years of age with myocardial infarction. J Am Med Assoc. 1951;146:1291–1295.
    1. Kannel WB, Castelli WP, McNamara PM. The coronary profile: 12-year follow-up in the Framingham study. J Occup Med. 1967;9:611–619.
    1. Kylin E. Studien ueber das Hypertonie-Hyperglyka "mie-Hyperurika" miesyndrom. Zentralblatt fuer Innere Medizin. 1923;44:105–127.
    1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.
    1. Zavaroni I, Mazza S, Fantuzzi M, Dall'Aglio E, Bonora E, Delsignore R, Passeri M, Reaven GM. Changes in insulin and lipid metabolism in males with asymptomatic hyperuricaemia. J Intern Med. 1993;234:25–30.
    1. Hayden MR, Tyagi SC. Intimal redox stress: Accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol. 2002;1:3. doi: 10.1186/1475-2840-1-3.
    1. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494–501.
    1. Hayden MR. Global risk reduction of reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy. Medical Hypotheses and Research. 2004;1:171–185.
    1. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275:457–464.
    1. Oxipurinol: alloxanthine, Oxyprim, oxypurinol. Drugs R D. 2004;5:171–175.
    1. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221–226. doi: 10.1161/01.CIR.0000022140.61460.1D.
    1. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105:2619–2624. doi: 10.1161/01.CIR.0000017502.58595.ED.
    1. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000;35:746–751.
    1. Lin KC, Tsao HM, Chen CH, Chou P. Hypertension was the major risk factor leading to development of cardiovascular diseases among men with hyperuricemia. J Rheumatol. 2004;31:1152–1158.
    1. Wu X, Wakamiya M, Vaishnav S, Geske R, Montgomery C, Jr, Jones P, Bradley A, Caskey CT. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci U S A. 1994;91:742–746.
    1. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101–1106.
    1. Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F, Burnier M. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health. 2004;4:9. doi: 10.1186/1471-2458-4-9.
    1. Ogura T, Matsuura K, Matsumoto Y, Mimura Y, Kishida M, Otsuka F, Tobe K. Recent trends of hyperuricemia and obesity in Japanese male adolescents, 1991 through 2002. Metabolism. 2004;53:448–453. doi: 10.1016/j.metabol.2003.11.017.
    1. Pan WH, Flegal KM, Chang HY, Yeh WT, Yeh CJ, Lee WC. Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. Am J Clin Nutr. 2004;79:31–39.
    1. Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatoryi V, Tosi F, Travia D, Zenti MG, Branzi P, Santi L, Muggeo M. Relationship of uric acid concentration to cardiovascular risk factors in young men. The role of obesity and central fat distribution, The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord. 1996;20:975–980.
    1. Bedir A, Topbas M, Tanyeri F, Alvur M, Arik N. Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J. 2003;44:527–536. doi: 10.1536/jhj.44.527.
    1. Williamson JR, Kilo C, Ido Y. The role of cytosolic reductive stress in oxidant formation and diabetic complications. Diabetes Res Clin Pract. 1999;45:81–82. doi: 10.1016/S0168-8227(99)00034-0.
    1. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol. 2002;1:1. doi: 10.1186/1475-2840-1-1.
    1. Santos CX, Anjos EI, Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys. 1999;372:285–294. doi: 10.1006/abbi.1999.1491.
    1. Abuja PM. Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett. 1999;446:305–308. doi: 10.1016/S0014-5793(99)00231-8.
    1. Hayden MR, Tyagi SC. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation. Nutr J. 2004;3:4. doi: 10.1186/1475-2891-3-4.
    1. Evers S, Koch HG, Grotemeyer KH, Lange B, Deufel T, Ringelstein EB. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol. 1997;54:1276–1282.
    1. Hong YS, Lee MJ, Kim KH, Lee SH, Lee YH, Kim BG, Jeong B, Yoon HR, Nishio H, Kim JY. The C677 mutation in methylene tetrahydrofolate reductase gene: correlation with uric acid and cardiovascular risk factors in elderly Korean men. J Korean Med Sci. 2004;19:209–213.
    1. Hayden MR, Tyagi SC. Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol. 2004;3:1. doi: 10.1186/1475-2840-3-1.
    1. Hayden MR, Tyagi SC. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol. 2003;2:2. doi: 10.1186/1475-2840-2-2.
    1. Jurgens G, Hoff HF, Chisolm GM, 3rd, Esterbauer H. Modification of human serum low density lipoprotein by oxidation – characterization and pathophysiological implications. Chem Phys Lipids. 1987;45:315–336. doi: 10.1016/0009-3084(87)90070-3.
    1. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest. 1996;97:1535–1544.
    1. Heinecke JW. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol. 2003;91:12A–16A. doi: 10.1016/S0002-9149(02)03145-4.
    1. Darley-Usmar VM, Hogg N, O'Leary VJ, Wilson MT, Moncada S. The simultaneous generation of superoxide and nitric oxide can initiate lipid peroxidation in human low density lipoprotein. Free Radic Res Commun. 1992;17:9–20.
    1. Hogg N, Darley-Usmar VM, Graham A, Moncada S. Peroxynitrite and atherosclerosis. Biochem Soc Trans. 1993;21:358–362.
    1. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 1994;94:437–444.
    1. Kuhn H, Belkner J, Suzuki H, Yamamoto S. Oxidative modification of human lipoproteins by lipoxygenases of different positional specificities. J Lipid Res. 1994;35:1749–1759.
    1. Bagnati M, Perugini C, Cau C, Bordone R, Albano E, Bellomo G. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem J. 1999;340:143–152. doi: 10.1042/0264-6021:3400143.
    1. Patterson RA, Horsley ET, Leake DS. Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. J Lipid Res. 2003;44:512–521. doi: 10.1194/jlr.M200407-JLR200.
    1. Nyyssonen K, Porkkala-Sarataho E, Kaikkonen J, Salonen JT. Ascorbate and urate are the strongest determinants of plasma antioxidative capacity and serum lipid resistance to oxidation in Finnish men. Atherosclerosis. 1997;130:223–233. doi: 10.1016/S0021-9150(96)06064-9.
    1. Naghavi M, John R, Naguib S, Siadaty MS, Grasu R, Kurian KC, van Winkle WB, Soller B, Litovsky S, Madjid M, Willerson JT, Casscells W. pH Heterogeneity of human and rabbit atherosclerotic plaques; a new insight into detection of vulnerable plaque. Atherosclerosis. 2002;164:27–35. doi: 10.1016/S0021-9150(02)00018-7.
    1. Sanguinetti SM, Batthyany C, Trostchansky A, Botti H, Lopez GI, Wikinski RL, Rubbo H, Schreier LE. Nitric oxide inhibits prooxidant actions of uric acid during copper-mediated LDL oxidation. Arch Biochem Biophys. 2004;423:302–308. doi: 10.1016/j.abb.2003.12.034.
    1. Vickers S, Schiller HJ, Hildreth JE, Bulkley GB. Immunoaffinity localization of the enzyme xanthine oxidase on the outside surface of the endothelial cell plasma membrane. Surgery. 1998;124:551–560. doi: 10.1067/msy.1998.89892.
    1. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109:2818–2825. doi: 10.1161/01.CIR.0000132467.45278.59.
    1. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41:1287–1293. doi: 10.1161/01.HYP.0000072820.07472.3B.
    1. Olexa P, Olexova M, Gonsorcik J, Tkac I, Kisel'ova J, Olejnikova M. Uric acid – a marker for systemic inflammatory response in patients with congestive heart failure? Wien Klin Wochenschr. 2002;114:211–215.
    1. Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, Murata C, Otsuka R, Zhu S, Toyoshima H. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord. 2003;27:443–449. doi: 10.1038/sj.ijo.0802260.
    1. Hu P, Seeman TE, Harris TB, Reuben DB. Is serum uric acid level associated with all-cause mortality in high-functioning older persons: MacArthur studies of successful aging? J Am Geriatr Soc. 2001;49:1679–1684. doi: 10.1046/j.1532-5415.2001.t01-1-49279.x.
    1. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes. Eur J Clin Invest. 2001;31:318–321. doi: 10.1046/j.1365-2362.2001.00812.x.
    1. Hsu SP, Pai MF, Peng YS, Chiang CK, Ho TI, Hung KY. Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients. Nephrol Dial Transplant. 2004;19:457–462. doi: 10.1093/ndt/gfg563.
    1. Lyu LC, Hsu CY, Yeh CY, Lee MS, Huang SH, Chen CL. A case-control study of the association of diet and obesity with gout in Taiwan. Am J Clin Nutr. 2003;78:690–701.
    1. Johnson RJ, Tuttle KR. Much ado about nothing, or much to do about something? The continuing controversy over the role of uric acid in cardiovascular disease. Hypertension. 2000;35:E10.

Source: PubMed

Подписаться